GRAIL Valuation
Is GRAL * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GRAL * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GRAL *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GRAL *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRAL *?
Other financial metrics that can be useful for relative valuation.
What is GRAL *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$403.45m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.8x |
Enterprise Value/EBITDA | -0.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GRAL *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 13.2x | ||
ORTX Orchard Therapeutics | 17.4x | 34.5% | US$380.1m |
ACIU AC Immune | 20.4x | 17.2% | US$337.3m |
AVCT Avacta Group | 10.4x | 10.8% | UK£241.8m |
ARCT Arcturus Therapeutics Holdings | 4.6x | 37.6% | US$577.7m |
GRAL * GRAIL | 4x | n/a | Mex$403.4m |
Price-To-Sales vs Peers: GRAL * is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (13.2x).
Price to Earnings Ratio vs Industry
How does GRAL *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: GRAL * is good value based on its Price-To-Sales Ratio (4x) compared to the Global Biotechs industry average (9.8x).
Price to Sales Ratio vs Fair Ratio
What is GRAL *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GRAL *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.